Amgen (AMGN) Amortization - Intangibles (2009 - 2012)
Amgen's quarterly Amortization - Intangibles came in at $73.0 million in Q4 2012, little changed year-on-year from $73.0 million in Q1 2012, and down 1.35% quarter-over-quarter from $74.0 million in Q3 2012.
Amgen has reported Amortization - Intangibles for 4 years, with the latest figure at $73.0 million in Q4 2012.
- For the quarter ending Q4 2012, Amortization - Intangibles changed 0.0% year-over-year to $73.0 million; the trailing twelve-month figure through Dec 2012 stood at $294.0 million (changed 0.0% YoY), and the FY2012 full-year result was $294.0 million, changed 0.0% from the prior year.
- Amortization - Intangibles for Q4 2012 stood at $73.0 million, down from $74.0 million in the prior quarter.
- The five-year high for Amortization - Intangibles was $74.0 million in Q1 2009, with the low at $73.0 million in Q2 2009.
- Average Amortization - Intangibles over 4 years is $73.5 million, with a median of $73.5 million recorded in 2009.
- Peak annual rise in Amortization - Intangibles reached 0.0% in 2010, while the deepest fall reached 0.0% in 2010.
- Tracing AMGN's Amortization - Intangibles over 4 years: stood at $73.0 million in 2009, then changed by 0.0% to $73.0 million in 2010, then changed by 0.0% to $73.0 million in 2011, then changed by 0.0% to $73.0 million in 2012.
- The last three Amortization - Intangibles figures came in at $73.0 million (Q4 2012), $74.0 million (Q3 2012), and $73.0 million (Q2 2012), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 73.00 Mn |
| Sep 30, 2012 | 74.00 Mn |
| Jun 30, 2012 | 73.00 Mn |
| Mar 31, 2012 | 74.00 Mn |
| Dec 31, 2011 | 73.00 Mn |
| Sep 30, 2011 | 74.00 Mn |
| Jun 30, 2011 | 73.00 Mn |
| Mar 31, 2011 | 74.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 74.00 Mn |
| Jun 30, 2010 | 73.00 Mn |
| Mar 31, 2010 | 74.00 Mn |
| Dec 31, 2009 | 73.00 Mn |
| Sep 30, 2009 | 74.00 Mn |
| Jun 30, 2009 | 73.00 Mn |
| Mar 31, 2009 | 74.00 Mn |